Sk Biopharmaceuticals Co Ltd (326030) - Total Liabilities

Latest as of December 2025: ₩372.04 Billion KRW ≈ $252.13 Million USD

Based on the latest financial reports, Sk Biopharmaceuticals Co Ltd (326030) has total liabilities worth ₩372.04 Billion KRW (≈ $252.13 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 326030 net asset momentum to track the company's year-over-year net asset growth rate.

Sk Biopharmaceuticals Co Ltd - Total Liabilities Trend (2016–2025)

This chart illustrates how Sk Biopharmaceuticals Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See 326030 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.

Sk Biopharmaceuticals Co Ltd Competitors by Total Liabilities

The table below lists competitors of Sk Biopharmaceuticals Co Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
ALMONTY INDUSTRIES CDIS/1 F:ALI0	Germany	€231.92 Million
InnoDisk TWO:5289	Taiwan	NT$5.43 Billion
PLDT Inc ADR NYSE:PHI	USA	$507.87 Billion
AAC TECHNOLOG.HLDG.ADR/ F:A2X	Germany	€23.27 Billion
Beijing New Building Materials Public Ltd Co SHE:000786	China	CN¥8.07 Billion
CSW Industrials, Inc. NYSE:CSW	USA	$1.20 Billion
Kulicke and Soffa Industries Inc F:KU1	Germany	€289.61 Million

Liability Composition Analysis (2016–2025)

This chart breaks down Sk Biopharmaceuticals Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 326030 market cap overview.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	2.31	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.46	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.31	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Sk Biopharmaceuticals Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Sk Biopharmaceuticals Co Ltd (2016–2025)

The table below shows the annual total liabilities of Sk Biopharmaceuticals Co Ltd from 2016 to 2025.

Year	Total Liabilities	Change
2025-12-31	₩372.04 Billion ≈ $252.13 Million	-19.62%
2024-12-31	₩462.83 Billion ≈ $313.65 Million	+15.07%
2023-12-31	₩402.22 Billion ≈ $272.58 Million	+15.69%
2022-12-31	₩347.68 Billion ≈ $235.62 Million	+74.31%
2021-12-31	₩199.46 Billion ≈ $135.17 Million	+64.61%
2020-12-31	₩121.17 Billion ≈ $82.12 Million	-20.33%
2019-12-31	₩152.10 Billion ≈ $103.07 Million	+312.12%
2018-12-31	₩36.91 Billion ≈ $25.01 Million	-27.81%
2017-12-31	₩51.12 Billion ≈ $34.65 Million	+10.64%
2016-12-31	₩46.21 Billion ≈ $31.31 Million	--

About Sk Biopharmaceuticals Co Ltd

KO:326030 Korea Biotechnology

Market Cap

$4.53 Billion

₩6.69 Trillion KRW

Market Cap Rank

#3814 Global

#84 in Korea

Share Price

₩85400.00

Change (1 day)

+2.28%

52-Week Range

₩74600.00 - ₩140700.00

All Time High

₩217000.00